XBiotech (NASDAQ:XBIT) Stock Crosses Below 50 Day Moving Average – Should You Sell?

Shares of XBiotech Inc. (NASDAQ:XBIT) crossed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $2.23 and traded as low as $2.15. XBiotech shares last traded at $2.16, with a volume of 78,397 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of XBiotech from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, September 28th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock has an average rating of “Sell”.

XBiotech Price Performance

The business has a 50 day moving average price of $2.23 and a two-hundred day moving average price of $2.32.

XBiotech (NASDAQ:XBIT) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.25).

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Empowered Funds LLC bought a new stake in shares of XBiotech during the 2nd quarter worth $137,000. Bank of America Corp DE purchased a new position in shares of XBiotech in the 2nd quarter worth about $55,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in XBiotech during the second quarter valued at about $64,000. BlackRock Inc. bought a new position in XBiotech during the second quarter valued at about $739,000. Finally, Bank of New York Mellon Corp bought a new position in XBiotech during the second quarter valued at about $91,000. Institutional investors own 55.70% of the company’s stock.

XBiotech Company Profile

XBiotech, Inc is a clinical-stage biotechnology company focused on developing therapies based on naturally occurring human antibodies. Its True Human antibody platform is designed to identify and produce antibody-based medicines that replicate immune proteins found in healthy individuals, with the goal of treating inflammatory, oncologic and other serious diseases.

The company’s leading candidate has been bermekimab, a monoclonal antibody that targets interleukin-1 alpha, an inflammatory protein involved in multiple disease processes.